17.22 0.00 (0.00%)
Pre-market: 4:48AM EST
|Bid||16.80 x 1100|
|Ask||17.22 x 4000|
|Day's range||16.98 - 17.29|
|52-week range||12.43 - 20.00|
|Beta (5Y monthly)||1.11|
|PE ratio (TTM)||21.22|
|Forward dividend & yield||0.85 (4.93%)|
|Ex-dividend date||29 Sep 2020|
|1y target est||N/A|
BioLife Plasma Services announces expansion of plasma donation centers into California.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") Takeda has been announced the winner of the EURORDIS 2021 Award for Patient Engagement in recognition of the company’s unwavering commitment to rare disease patients and its comprehensive partnerships with the rare disease patient community.